Suggested remit: To appraise the clinical and cost effectiveness of atogepant within its marketing authorisation for preventing migraine.
Status
|
In progress
|
Technology type
|
Medicine
|
Decision
|
Selected
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
Further information
|
DHSC referral received
|
Process |
TA
|
ID number |
5090
|
Provisional Schedule
Expected publication |
15 May 2024 |
Project Team
Project lead |
Celia Mayers |
Email enquiries
External Assessment Group |
BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
Companies sponsors |
AbbVie (atogepant) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
Migraine Trust |
Professional groups |
Association of British Neurologists |
|
British Pain Society |
|
Royal College of Physicians |
|
UK Clinical Pharmacy Association |
Comparator companies |
AbbVie (botulinum toxin type A) |
|
Eli Lilly (galcanezumab) |
|
Lundbeck (eptinezumab) |
|
Novartis (erenumab) |
|
Pfizer (rimegepant) |
|
Teva UK (fremanezumab) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
National Institute for Health Research |
Date
|
Update
|
11 April 2024 - 25 April 2024
|
Final draft guidance |
08 February 2024
|
Committee meeting |
05 October 2023
|
This topic will continue as a single technology appraisal (STA) rather than a cost comparison appraisal.
The company, AbbVie, will be submitting evidence in late September 2023. The first committee meeting will be held on 8 February 2024. |
18 January 2023
|
Invitation to participate |
18 January 2023
|
We have selected atogepant for preventing migraine for a pilot for the proportional approach to technology appraisals sub process: a streamlined approach to Cost Comparison Appraisals.
We believe efficiencies can be made to the current cost comparison approach which would result in a faster route to a recommendation for companies, quicker access for patients and a less resource intensive process for all involved. There will be a shorter submission period and external assessment group (EAG) review of the company’s evidence submission. In late April 2023, NICE will advise a subset of the committee (the chair and vice chair) of the appropriateness of cost comparison. This subset will review the evidence online over a set period and be able to make a recommendation outside of a full committee meeting. This will not alter standard governance or appeal processes and maintains the independence of the committee as a decision-making body. |
06 September 2022 - 04 October 2022
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
07 July 2022
|
In progress |
22 March 2022
|
Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual